A group of 42 states, led by Wisconsin, can move forward with legal action against the makers of a drug used to treat opioid dependence.
The announcement comes after a ruling by the Court in the Eastern District of Pennsylvania, saying they can proceed with a lawsuit. Wisconsin Assistant Attorney General for Antitrust Gwendolyn Lindsay Cooley is at the head of the investigation, along with states that include Illinois, Iowa and Minnesota.
The group of states accuse Indivior Inc. of illegally shifted the market for the drug, Suboxone, from tablets to film in an attempt to eradicate the demand for tablets. It’s alleged that the company is doing this to preserve its monopoly on the drug.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
NCAA and SEC Approve Historic $2.8 Billion Settlement in Antitrust Cases
May 23, 2024 by
CPI
Apple Defends 27% Fee in Compliance with Court Order, Phil Schiller Testifies
May 23, 2024 by
CPI
French Billionaire Xavier Niel Eyes $4 Billion Millicom Buyout
May 23, 2024 by
CPI
ITA-Lufthansa Merger Faces Scrutiny from European Commission
May 23, 2024 by
CPI
Google Explores Major Acquisition of HubSpot to Bolster Cloud
May 23, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI